Related references
Note: Only part of the references are listed.Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
Nicola Colclough et al.
CLINICAL CANCER RESEARCH (2021)
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study
Aurelija Jucaite et al.
NEURO-ONCOLOGY (2021)
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer
Andrea Varrone et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The blood-brain barrier and blood-tumour barrier in brain tumours and metastases
Costas D. Arvanitis et al.
NATURE REVIEWS CANCER (2020)
Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET
Remy B. Verheijen et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Understanding brain penetrance of anticancer drugs
Victor A. Levin et al.
NEURO-ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Thanyanan Reungwetwattana et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization
Negar Chooback et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
G. Goss et al.
ANNALS OF ONCOLOGY (2018)
High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases
Mengxi Ge et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
David Planchard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer
Solange Peters et al.
CANCER TREATMENT REVIEWS (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
Hermann Reichegger et al.
ONCOLOGY RESEARCH AND TREATMENT (2016)
Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates
Magnus Schou et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
Deepa Rangachari et al.
LUNG CANCER (2015)
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
Azeem Saleem et al.
EJNMMI RESEARCH (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Share Paper
